Intra ocular injection of Bevacizumab and Triamcinolone for diabetic visual loss.
- Conditions
- Health Condition 1: null- DIABETES MELLITUS
- Registration Number
- CTRI/2014/09/005070
- Lead Sponsor
- ethradhama Superspeciality Eye Hospita
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 15
•All Patients with clinically significant macular oedema (according to ETDRS study) with systemic diabetis mellitus of > 3 months duration.
•Patients were required to have a baseline CRT of at least 300 um and BCVA of 20/25 to 20/400 Snellen equivalent in the study eye.
•Patients with HbA1c controlled at less than 8.0% at the beginning and during the study duration.
Patients with bilateral macular oedema, with retinal thickness difference between two eyes of >100um.
Patient with history of
•Macular Laser Photocoagulation
•Intravitreal Injection Therapy
•Active Proliferative Diabetic Retinopathy (PDRP) With Necessity Of Panretinal Laser Treatment
•Panretinal Laser Treatment Within The Past 3 Months
•Previous vitreous surgery
•IHD & CVA
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method